Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. * Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice 54321 The information and/or skills learned will enhance my professional competence or ability. The information and/or skills learned will enhance my professional competence or ability. - 5 The information and/or skills learned will enhance my professional competence or ability. - 4 The information and/or skills learned will enhance my professional competence or ability. - 3 The information and/or skills learned will enhance my professional competence or ability. - 2 The information and/or skills learned will enhance my professional competence or ability. - 1 This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5 This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4 This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3 This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2 This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1 As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives * Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice 54321 Describe how the identification of driver mutations in lung cancer has resulted in tremendous clinical impact for patients. Describe how the identification of driver mutations in lung cancer has resulted in tremendous clinical impact for patients. - 5 Describe how the identification of driver mutations in lung cancer has resulted in tremendous clinical impact for patients. - 4 Describe how the identification of driver mutations in lung cancer has resulted in tremendous clinical impact for patients. - 3 Describe how the identification of driver mutations in lung cancer has resulted in tremendous clinical impact for patients. - 2 Describe how the identification of driver mutations in lung cancer has resulted in tremendous clinical impact for patients. - 1 Implement the use of technology that has provided alternatives to diagnose tumor tissues in patients. Implement the use of technology that has provided alternatives to diagnose tumor tissues in patients. - 5 Implement the use of technology that has provided alternatives to diagnose tumor tissues in patients. - 4 Implement the use of technology that has provided alternatives to diagnose tumor tissues in patients. - 3 Implement the use of technology that has provided alternatives to diagnose tumor tissues in patients. - 2 Implement the use of technology that has provided alternatives to diagnose tumor tissues in patients. - 1 Initiating immunotherapy through immune checkpoint inhibition is also an effective alternative for treatment in patients with no driver mutations. Initiating immunotherapy through immune checkpoint inhibition is also an effective alternative for treatment in patients with no driver mutations. - 5 Initiating immunotherapy through immune checkpoint inhibition is also an effective alternative for treatment in patients with no driver mutations. - 4 Initiating immunotherapy through immune checkpoint inhibition is also an effective alternative for treatment in patients with no driver mutations. - 3 Initiating immunotherapy through immune checkpoint inhibition is also an effective alternative for treatment in patients with no driver mutations. - 2 Initiating immunotherapy through immune checkpoint inhibition is also an effective alternative for treatment in patients with no driver mutations. - 1 Rate the following * Scoring Key: 5=Excellent 4=Very Good 3=Good 2=Fair 1=Poor 54321 Course content. Course content. - 5 Course content. - 4 Course content. - 3 Course content. - 2 Course content. - 1 Miguel A. Villalona- Calero, M.D., FACP, FAAAS Miguel A. Villalona- Calero, M.D., FACP, FAAAS - 5 Miguel A. Villalona- Calero, M.D., FACP, FAAAS - 4 Miguel A. Villalona- Calero, M.D., FACP, FAAAS - 3 Miguel A. Villalona- Calero, M.D., FACP, FAAAS - 2 Miguel A. Villalona- Calero, M.D., FACP, FAAAS - 1 Was this course fair, balanced and without commercial bias? * Yes No If you checked "No,” please explain why: * How many patients will you see in your practice who will likely be impacted by what you learned at this activity? * 1-5 6-10 Over 10 Not applicable to my practice Please list specific changes you intend to implement in your daily practice as a result of attending this activity. * If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so. * Comments Please select one: * M.D., D.O. Ph.D. Psy.D. DPM PA-C ARNP R.N. Pharmacist Respiratory Therapist SW/MFT/MHC Other... Please select one: Other... Name Leave this field blank
